ADC Congress Asia 2026: (SG Biopharma/ Academic)

The ADC Asia Congress 2026 stands as Asia’s premier conference for research, development, and manufacturing in the Antibody-Drug Conjugate (ADC) sector, uniting leading stakeholders across the region. The ADC industry is entering a transformative phase, with a surge of collaborations, innovations, and deals positioning Asia as a hub for next-generation ADC development. Advancements go beyond traditional biosimilars, exploring novel payloads, linkers, and conjugation technologies, driven by the rising global incidence of cancer and the demand for more precise and effective therapies. Breakthroughs in antibody engineering are enhancing ADC specificity and efficacy, while growing investments and increasing FDA approvals underscore the sector’s potential and regulatory confidence. At the same time, the industry faces significant challenges, including high development costs, complex manufacturing, and potential toxicities, necessitating strategic planning and innovative solutions. The Congress will provide a vital platform for pioneers, key opinion leaders, and experts from mega-pharma and biotechnology across Singapore, China, Japan, South Korea, Australia, and the wider Asia-Pacific region to discuss the latest technological advances, clinical developments, strategic partnerships, and shared challenges in ADC development.